Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223. Although the patient ultimately died from causes unrelated...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobashi, Masato, Kouguchi, Dai, Kanetsuna, Yukiko, Ishii, Junichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218028/
https://www.ncbi.nlm.nih.gov/pubmed/32420038
http://dx.doi.org/10.1016/j.eucr.2020.101230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218028/
https://www.ncbi.nlm.nih.gov/pubmed/32420038
http://dx.doi.org/10.1016/j.eucr.2020.101230

Ejemplares similares